CN-122005521-A - Use of 3-chloro-N-ethyl-N- (o-tolyl) butanamide for the preparation of a product for the treatment of tumors

Abstract

The invention relates to application of 3-chloro-N-ethyl-N- (o-tolyl) butyramide in preparing a product for treating tumors, belonging to the technical field of medicines for treating tumors. The technical problem to be solved is to provide a new application of 3-chloro-N-ethyl-N- (o-tolyl) butyramide. The technical scheme is characterized in that the 3-chloro-N-ethyl-N- (o-tolyl) butyramide is used for preparing a product for treating tumors.

Inventors

• LV JIUAN
• SU WENJING
• GUAN HAIQUAN
• FAN JIPING

Assignees

• 北京红惠新医药科技有限公司

Dates

Publication Date

20260512

Application Date

20260317

Claims (7)

1. Use of 3-chloro-N-ethyl-N- (o-tolyl) butanamide for the preparation of a product for the treatment of tumors, the structural formula of 3-chloro-N-ethyl-N- (o-tolyl) butanamide being as follows: 。
2. 2. the use according to claim 1, wherein the tumour is colorectal cancer.
3. 3. The use according to claim 1, wherein the treatment of a tumor is inhibition of proliferation, migration and/or invasion of colorectal cancer cells.
4. 4. The use according to claim 1, wherein the product further comprises pharmaceutically acceptable excipients.
5. 5. The use according to claim 4, wherein the pharmaceutically acceptable excipients comprise at least one of solvents, diluents, disintegrants, precipitation inhibitors, surfactants, glidants, binders, lubricants, dispersants, suspending agents, isotonic agents, thickening agents, emulsifiers, preservatives, stabilizers, hydration agents, emulsification accelerators, buffers, absorbents, colorants, fragrances, sweeteners, ion exchangers, flavoring agents, and antioxidants.
6. 6. The use according to claim 1, wherein the product further comprises other medicaments for the prevention and/or treatment of tumors.
7. 7. The use according to claim 6, wherein the other drugs comprise at least one of platinum drugs, targeted therapeutic drugs, antitumor antibiotics, antitumor drugs of plant origin and antimetabolites.

Description

Use of 3-chloro-N-ethyl-N- (o-tolyl) butanamide for the preparation of a product for the treatment of tumors Technical Field The invention relates to the technical field of medicines for treating tumors, in particular to application of 3-chloro-N-ethyl-N- (o-tolyl) butyramide in preparing a product for treating tumors. Background A plurality of N-substituted amides (N-Substituted Amides) have wide potential in anti-tumor research, and mainly play roles in inhibiting tumor cell proliferation, inducing apoptosis, blocking angiogenesis or inhibiting microtubule polymerization and other mechanisms. The related patent documents: publication No. CN108997176A, publication No. 2018, 12-month 14, discloses the activity of 4-chloro-N-substituted phenyl-3-sulfonylaminobenzamide compounds in anti-tumor aspect, wherein one of the compounds has the following structural formula: 。 the relevant non-patent literature: Journal name or book name "pharmaceutical journal", literature name "synthesis and antitumor Activity of N-substituted benzamide derivatives", volume 44, publication date 2009, which discloses different activities of 11 different N-substituted benzamide derivatives in antitumor aspect. 3-Chloro-N-ethyl-N- (o-tolyl) butanamide, also known as 3-chloro-N-ethyl-N- (2-methylphenyl) butanamide, having the formula: 。 none of the prior art discloses the therapeutic activity of 3-chloro-N-ethyl-N- (o-tolyl) butanamide in terms of antitumor activity. Disclosure of Invention The invention aims to provide that: The application of 3-chloro-N-ethyl-N- (o-tolyl) butyramide in preparing a product for treating tumors and the related technology thereof are provided for solving the technical problems of providing a new application of 3-chloro-N-ethyl-N- (o-tolyl) butyramide and the like or the combination thereof. Description of the terminology: unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the inventive subject matter belongs. All patents, patent inventions, and publications cited herein are incorporated by reference in their entirety unless otherwise indicated. If there are multiple definitions of terms herein, the definitions of this chapter shall control. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the subject matter of the invention, as claimed. In the present invention, the singular is used to include the plural unless specifically stated otherwise. It should also be noted that the use of "or" means "and/or" unless stated otherwise. Furthermore, the terms "include," as well as other forms, such as "comprising," "including," and "containing," are not limiting. The definition of standard chemical terms can be found in reference "Li Qiu, zhang Xiaoshi, tumor drug treatment regimens and comprehensive evaluation [ M ]. People health press 2020". Unless otherwise indicated, conventional methods within the skill in the art, such as nuclear magnetic resonance hydrogen spectroscopy (1H NMR) test methods, mass spectrometry (ESI-MS) test methods, compound purity analysis methods, and antitumor activity test methods, are employed. Wherein, the purity analysis method of the compound adopts a Gas Chromatography (GC) method, and the anti-tumor activity test method adopts an MTT method. Unless specifically defined, the use of various commercially available products as used herein employs standard techniques. For example, the kit may be used by the manufacturer, or may be implemented in a manner known in the art or in accordance with the description of the invention. The techniques and methods described above may generally be practiced according to conventional methods well known in the art, based on a number of general and more specific descriptions in the literature cited and discussed in this specification. The term "optionally/arbitrarily" or "optionally/arbitrarily" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. The term "pharmaceutically acceptable adjuvant" as used herein refers to pharmaceutically acceptable materials such as liquid or solid fillers, stabilizers, dispersants, suspending agents, diluents, excipients, thickeners, solvents or encapsulating materials, which are involved in carrying or transporting any pharmaceutical composition from one organ or portion of the body to another organ or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical composition and not deleterious to the patient. The term "treatment" as used herein refers to obtaining a desired pharmacological and/or physiological effect. The effect may be, but need not necessarily be, prophylacti